Clinical Reviews in Allergy & Immunology

, Volume 38, Issue 1, pp 3–10 | Cite as

Chronic Granulomatous Disease

  • Steven M. HollandEmail author


Chronic granulomatous disease (CGD) was first described in the 1950s and has become a paradigm for genetic neutrophil diseases. It is characterized by recurrent infections with a narrow spectrum of bacteria and fungi as well as a common set of inflammatory complications most notably including inflammatory bowel disease. Over the last half century major advances in management have profoundly altered the major clinical issues and the life expectancy of CGD. With X-linked and autosomal recessive forms, it has been an important disease for the development of bone marrow transplantation and gene therapy. Some of the recent developments in infectious syndromes, inflammatory complications, and curative approaches are discussed in this review.


Chronic granulomatous disease (CGD) X-linked disease NADPH oxidase Nitroblue tetrazolium (NBT) Dihydrorhodamine oxidation (DHR) Aspergillus Granulibacter Burkholderia 



This work supported by the Division of Intramural Research, NIAID, NIH.


  1. 1.
    Janeway CA, Craig J, Davidson M, Downey W, Gitlin D, Sullivan JC (1954) Hypergammaglobulinemia associated with severe, recurrent and chronic non-specific infection. Am J Dis Child 88:388–392Google Scholar
  2. 2.
    Berendes H, Bridges RA, Good RA (1957) A fatal granulomatous disease of childhood: the clinical study of a new syndrome. Minn Med 40:309PubMedGoogle Scholar
  3. 3.
    Bridges RA, Berendes H, Good RA (1959) A fatal granulomatous disease of childhood. Am J Dis Child 97:387Google Scholar
  4. 4.
    Azimi PH, Bodenbender JG, Hintz RL, Kontras SB (1968) Chronic granulomatous disease in three female siblings. JAMA 206:2865–2870CrossRefPubMedGoogle Scholar
  5. 5.
    Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM (2000) Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79:170–200CrossRefGoogle Scholar
  6. 6.
    Ushio-Fukai M (2006) Localizing NADPH oxidase-derived ROS. Sci STKE 349:re8CrossRefGoogle Scholar
  7. 7.
    Reeves EP, Lu H, Jacobs HL, Messina CGM, Bolsover S, Gabella G, Potma EO, Warley A, Roes J, Segal AW (2002) Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 416:291–297CrossRefPubMedGoogle Scholar
  8. 8.
    Wolach B, Gavrieli R, de Boer M, Gottesman G, Ben-Ari J, Rottem M, Schlesinger Y, Grisaru-Soen G, Etzioni A, Roos D (2008) Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin Immunol 129:103–114CrossRefPubMedGoogle Scholar
  9. 9.
    Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs HD, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79:155–169CrossRefGoogle Scholar
  10. 10.
    Lublin M, Bartlett DL, Danforth DN, Kauffman H, Gallin JI, Malech HL, Shawker T, Choyke P, Kleiner DE, Schwartzentruber DJ, Chang R, DeCarlo ES, Holland SM (2002) Hepatic abscess in patients with chronic granulomatous disease. Ann Surg 235:383–391CrossRefPubMedGoogle Scholar
  11. 11.
    Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, Rossi P, Gattorno M, Rabusin M, Azzari C, Dellepiane RM, Pietrogrande MC, Trizzino A, Di Bartolomeo P, Martino S, Carpino L, Cossu F, Locatelli F, Maccario R, Pierani P, Putti MC, Stabile A, Notarangelo LD, Ugazio AG, Plebani A, De Mattia D, IPINET (2008) Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol 126:155–164CrossRefPubMedGoogle Scholar
  12. 12.
    Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, Eisenstein EM, Turner ML, DeCarlo ES, Starling JM, Holland SM (2003) Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 348:2416–2422CrossRefPubMedGoogle Scholar
  13. 13.
    Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, Malech HL, Gallin JI, Holland SM (2004) Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 39:692–699CrossRefPubMedGoogle Scholar
  14. 14.
    Soncini E, Slatter MA, Jones LB, Hughes S, Hodges S, Flood TJ, Barge D, Spickett GP, Jackson GH, Collin MP, Abinun M, Cant AJ, Gennery AR (2009) Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 145:73–83CrossRefPubMedGoogle Scholar
  15. 15.
    Kobayashi S, Murayama S, Takanashi S, Takahashi K, Miyatsuka S, Fujita T, Ichinohe S, Koike Y, Kohagizawa T, Mori H, Deguchi Y, Higuchi K, Wakasugi H, Sato T, Wada Y, Nagata M, Okabe N, Tatsuzawa O (2008) Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr 167:1389–1394CrossRefPubMedGoogle Scholar
  16. 16.
    Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C (1989) Incidence, severity and prevention of infections in chronic granulomatous disease. J Pediatr 114:555–560CrossRefPubMedGoogle Scholar
  17. 17.
    Margolis DM, Melnick DA, Alling DW, Gallin JI (1990) Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 162:723–726PubMedGoogle Scholar
  18. 18.
    Ross JP, Holland SM, Gill VJ, DeCarlo ES, Gallin JI (1995) Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated cases. Clin Infect Dis 21:1291–1293PubMedGoogle Scholar
  19. 19.
    Kennedy MP, Coakley RD, Donaldson SH, Aris RM, Hohneker K, Wedd JP, Knowles MR, Gilligan PH, Yankaskas JR (2007) Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center. J Cyst Fibros 6:267–273CrossRefPubMedGoogle Scholar
  20. 20.
    Sirinavin S, Techasaensiri C, Benjaponpitak S, Pornkul R, Vorachit M (2005) Invasive Chromobacterium violaceum infection in children: case report and review. Pediatr Infect Dis J 24:559–561CrossRefPubMedGoogle Scholar
  21. 21.
    Mailman TL, Schmidt MH (2005) Francisella philomiragia adenitis and pulmonary nodules in a child with chronic granulomatous disease. Can J Infect Dis Med Microbiol 16:245–248PubMedGoogle Scholar
  22. 22.
    Greenberg DE, Ding L, Zelazny AM, Stock F, Wong A, Anderson VL, Miller G, Kleiner DE, Tenorio AR, Brinster L, Dorward DW, Murray PR, Holland SM (2006) A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog 2:e28CrossRefPubMedGoogle Scholar
  23. 23.
    López FC, de Luna FF, Delgado MC, de la Rosa II, Valdezate S, Nieto JA, Casal M (2008) Granulibacter bethesdensis isolated in a child patient with chronic granulomatous disease. J Infect 57:275–277CrossRefPubMedGoogle Scholar
  24. 24.
    Williamson PR, Kwon-Chung KJ, Gallin JI (1992) Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis 14:1023–1026PubMedGoogle Scholar
  25. 25.
    Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM (1998) Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 77:345–354CrossRefGoogle Scholar
  26. 26.
    Vinh DC, Shea YR, Sugui JA, Parrilla-Castellar ER, Freeman AF et al (2009) Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis (in press)Google Scholar
  27. 27.
    Vinh DC, Freeman AF, Shea YR, Malech HL, Abinun M, Weinberg GA, Holland SM (2009) Mucormycosis in chronic granulomatous disease: association with iatrogenic immunosuppression. J Allergy Clin Immunol (in press)Google Scholar
  28. 28.
    Morgenstern DE, Gifford MA, Li LL, Doerschuk CM, Dinauer MC (1997) Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med 185:207–218CrossRefPubMedGoogle Scholar
  29. 29.
    Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H, Witebsky FG, Shea YR, Gallin JI, Malech HL, Holland SM (2007) Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 45:673–681CrossRefPubMedGoogle Scholar
  30. 30.
    Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O’Brien S, Hilligoss DM, Malech HL, Gallin JI, Holland SM (2004) Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 114:462–468CrossRefPubMedGoogle Scholar
  31. 31.
    Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW (2009) Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am J Gastroenterol 104:117–124CrossRefPubMedGoogle Scholar
  32. 32.
    Hussain N, Feld JJ, Kleiner DE, Hoofnagle JH, Garcia-Eulate R, Ahlawat S, Koziel DE, Anderson V, Hilligoss D, Choyke P, Gallin JI, Liang TJ, Malech HL, Holland SM, Heller T (2007) Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology 45:675–683CrossRefPubMedGoogle Scholar
  33. 33.
    Feld JJ, Hussain N, Wright EC, Kleiner DE, Hoofnagle JH, Ahlawat S, Anderson V, Hilligoss D, Gallin JI, Liang TJ, Malech HL, Holland SM, Heller T (2008) Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 134:1917–1926CrossRefPubMedGoogle Scholar
  34. 34.
    Walther MM, Malech HL, Berman A, Choyke P, Venzon DJ, Linehan WM, Gallin JI (1992) The urologic manifestations of chronic granulomatous disease. J Urol 147:1314–1318PubMedGoogle Scholar
  35. 35.
    Bendhack ML, Vögeli T, Schroten H, Gerharz CD, Ackermann R (1997) Chronic granulomatous disease masquerading as a bladder tumor: a potential source of diagnostic error. Eur Urol 32:380–384PubMedGoogle Scholar
  36. 36.
    Kis E, Verebély T, Mészner Z (2002) Inflammatory pseudotumor of the bladder in chronic granulomatous disease. Pediatr Nephrol 17:220–221CrossRefPubMedGoogle Scholar
  37. 37.
    Hauck F, Heine S, Beier R, Wieczorek K, Müller D, Hahn G, Gahr M, Rösen-Wolff A, Roesler J (2008) Chronic granulomatous disease (CGD) mimicking neoplasms: a suspected mediastinal teratoma unmasking as thymic granulomas due to X-linked CGD, and 2 related cases. J Pediatr Hematol Oncol 30:877–880CrossRefPubMedGoogle Scholar
  38. 38.
    Barese CN, Podestá M, Litvak E, Villa M, Rivas EM (2004) Recurrent eosinophilic cystitis in a child with chronic granulomatous disease. J Pediatr Hematol Oncol 26:209–212CrossRefPubMedGoogle Scholar
  39. 39.
    Elloumi HZ, Holland SM (2007) Diagnostic assays for chronic granulomatous disease and other neutrophil disorders. Methods Mol Biol 412:505–523CrossRefPubMedGoogle Scholar
  40. 40.
    Mauch L, Lun A, O’Gorman MR, Harris JS, Schulze I, Zychlinsky A, Fuchs T, Oelschlägel U, Brenner S, Kutter D, Rösen-Wolff A, Roesler J (2007) Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem 53:890–896CrossRefPubMedGoogle Scholar
  41. 41.
    Ferguson PJ, Lokuta MA, El-Shanti HI, Muhle L, Bing X, Huttenlocher A (2008) Neutrophil dysfunction in a family with a SAPHO syndrome-like phenotype. Arthritis Rheum 58:3264–3269CrossRefPubMedGoogle Scholar
  42. 42.
    Roos D, van Zwieten R, Wijnen JT, Gomez-Gallego F, de Boer M, Stevens D, Pronk-Admiraal CJ, de Rijk T, van Noorden CJ, Weening RS, Vulliamy TJ, Ploem JE, Mason PJ, Bautista JM, Khan PM, Beutler E (1999) Molecular basis and enzymatic properties of glucose-6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 94:2955–2962PubMedGoogle Scholar
  43. 43.
    Rösen-Wolff A, Soldan W, Heyne K, Bickhardt J, Gahr M, Roesler J (2001) Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age-related skewing of lyonization. Ann Hematol 80:113–115CrossRefPubMedGoogle Scholar
  44. 44.
    Brandrup F, Koch C, Petri M, Schiodt M, Johansen KS (1981) Discoid lupus erythematosus-like lesions and stomatitis in female carriers of X-linked chronic granulomatous disease. Br J Dermatol 104:495–505CrossRefPubMedGoogle Scholar
  45. 45.
    Kragballe K, Borregaard N, Brandrup F, Koch C, Staehrjohansen K (1981) Relation of monocyte and neutrophil oxidative metabolism to skin and oral lesions in carriers of chronic granulomatous disease. Clin Exp Immunol 43:390–398PubMedGoogle Scholar
  46. 46.
    Rupec RA, Petropoulou T, Belohradsky BH, Walchner M, Liese JG, Plewing G, Messer G (2000) Lupus erythematosus tumidus and chronic discoid lupus erythematosus in carriers of X-linked chronic granulomatous disease. Eur J Dermatol 10:184–189PubMedGoogle Scholar
  47. 47.
    International Chronic Granulomatous Disease Cooperative Study Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324:509–516Google Scholar
  48. 48.
    Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA (1991) In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 163:849–852PubMedGoogle Scholar
  49. 49.
    Jackson SH, Miller GF, Segal BH, Mardiney M 3rd, Domachowske JB, Gallin JI, Holland SM (2001) IFN-gamma is effective in reducing infections in the mouse model of chronic granulomatous disease (CGD). J Interferon Cytokine Res 21:567–573CrossRefPubMedGoogle Scholar
  50. 50.
    Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, Flood T, Landais P, Müller S, Ozsahin H, Passwell JH, Porta F, Slavin S, Wulffraat N, Zintl F, Nagler A, Cant A, Fischer A (2002) Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood 100:4344–4350CrossRefPubMedGoogle Scholar
  51. 51.
    Kamani N, August CS, Campbell DE, Hassan NF, Douglas SD (1988) Marrow transplantation in chronic granulomatous disease: an update with 6 year follow-up. J Pediatr 113:697–700CrossRefPubMedGoogle Scholar
  52. 52.
    Ozsahin H, von Planta M, Muller I, Steinert HC, Nadal D, Lauener R, Tuchschmid P, Willi UV, Ozsahin M, Crompton NE, Seger RA (1998) Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 92:2719–2724PubMedGoogle Scholar
  53. 53.
    Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, Holland SM, Linton GF, Miller JA, Leitman SF, Read EJ, Malech HL (2001) Treatment of chronic granulomatous disease with nonmyeloablative conditioning and T-cell-depleted hematopoietic allograft. N Engl J Med 344:881–888CrossRefPubMedGoogle Scholar
  54. 54.
    Seger RA (2008) Modern management of chronic granulomatous disease. Br J Haematol 140:255–266CrossRefPubMedGoogle Scholar
  55. 55.
    Kang EM, Malech HL (2008) Advances in treatment for chronic granulomatous disease. Immunol Res 43:77–84CrossRefGoogle Scholar
  56. 56.
    Cavazzana-Calvo M, Fischer A (2007) Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 117:1456–1465CrossRefPubMedGoogle Scholar
  57. 57.
    Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Butz RE, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Gallin JI (1997) Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 94:12133–12138CrossRefPubMedGoogle Scholar
  58. 58.
    Ryser MF, Roesler J, Gentsch M, Brenner S (2007) Gene therapy for chronic granulomatous disease. Expert Opin Biol Ther 7:1799–1809CrossRefPubMedGoogle Scholar
  59. 59.
    Kono H, Rusyn I, Yin M, Gäbele E, Yamashina S, Dikalova A, Kadiiska MB, Connor HD, Mason RP, Segal BH, Bradford BU, Holland SM, Thurman RG (2000) NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 106:867–872CrossRefPubMedGoogle Scholar
  60. 60.
    Rusyn I, Kadiiska MB, Dikalova A, Kono H, Yin M, Tsuchiya K, Mason RP, Peters JM, Gonzalez FJ, Segal BH, Holland SM, Thurman RG (2001) Phthalates rapidly increase production of reactive oxygen species in vivo: role of Kupffer cells. Mol Pharmacol 59:744–750PubMedGoogle Scholar
  61. 61.
    Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS (2001) p47phox is required for atherosclerotic lesion progression in ApoE(−/−) mice. J Clin Invest 108:1513–1522PubMedGoogle Scholar
  62. 62.
    Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, Finkel T (2000) Vascular effects following homozygous disruption of p47(phox): an essential component of NADPH oxidase. Circulation 101:1234–1236PubMedGoogle Scholar
  63. 63.
    Kishida KT, Hoeffer CA, Hu D, Pao M, Holland SM, Klann E (2006) Synaptic plasticity deficits and mild memory impairments in mouse models of chronic granulomatous disease. Mol Cell Biol 26:5908–5920CrossRefPubMedGoogle Scholar
  64. 64.
    Pao M, Wiggs EA, Anastacio MM, Hyun J, DeCarlo ES, Miller JT, Anderson VL, Malech HL, Gallin JI, Holland SM (2004) Cognitive function in patients with chronic granulomatous disease: a preliminary report. Psychosomatics 45:230–234CrossRefPubMedGoogle Scholar
  65. 65.
    Walder CE, Green SP, Darbonne WC, Mathias J, Rae J, Dinauer MC, Curnutte JT, Thomas GR (1997) Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke 28:2252–2258PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  1. 1.Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious DiseasesNational Institutes of Health, Department of Health and Human ServicesBethesdaUSA

Personalised recommendations